论文部分内容阅读
目的探讨扶正消异方预防卵巢子宫内膜异位囊肿术后复发的效果。方法选取2010年1月~2011年10月间在该院行手术治疗的卵巢子宫内膜异位囊肿患者106例,随机分为观察组和对照组,每组53例。对照组术后给予经腹部皮下注射戈舍瑞林基础治疗;观察组在此基础上给予扶正消异方辨治。比较两组患者的疗效、复发情况、免疫指标及不良反应。结果观察组治疗总有效率明显高于对照组(P<0.05)。观察组患者术后半年、术后1年、术后2年、术后3年病情复发率均明显低于对照组(P<0.05)。治疗前两组各免疫指标之间差异均无统计学意义(P>0.05);治疗后两组CA125、EMAb、CD8水平均明显低于治疗前,CD3、CD4水平明显高于治疗前(P<0.05);观察组治疗后各免疫指标改善程度明显优于对照组(P<0.05)。观察组治疗期间不良反应发生率明显低于对照组(P<0.05)。结论扶正消异方可有效预防卵巢子宫内膜异位囊肿术后复发,提升机体的免疫功能,降低不良反应发生率。
Objective To investigate the effect of Fuzheng Haishifang on the recurrence after ovarian endometriosis cyst. Methods A total of 106 patients with ovarian endometriosis undergoing surgery in our hospital from January 2010 to October 2011 were randomly divided into observation group and control group, with 53 cases in each group. The control group was given subcutaneous Goserelin basic treatment by abdominal subcutaneous injection; the observation group was given Fuzheng Haishifang treatment. The curative effect, recurrence, immune index and adverse reaction of two groups were compared. Results The total effective rate of observation group was significantly higher than that of control group (P <0.05). The patients in the observation group had a significantly lower rate of relapse after six months, one year, two years and three years after operation than those in the control group (P <0.05). The levels of CA125, EMAb and CD8 in the two groups after treatment were significantly lower than those before treatment, and the levels of CD3 and CD4 in the two groups were significantly higher than those before treatment (P < 0.05). The improvement of each immune index in observation group was better than that in control group (P <0.05). The incidence of adverse reactions in observation group during treatment was significantly lower than that in control group (P <0.05). Conclusion Fuzhengxifen can effectively prevent ovarian endometriosis recurrence after surgery to enhance the body’s immune function and reduce the incidence of adverse reactions.